THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Drug giant to buy Sirtris for $720m

GlaxoSmithKline deal latest in flurry of local purchases

By Todd Wallack
Globe Staff / April 23, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Sirtris Pharmaceuticals Inc., the Cambridge biotech company that has attracted national attention for trying to use drugs based on an extract in red wine to fight diabetes and other age-related diseases, is being sold to British pharmaceuticals giant GlaxoSmithKline PLC for $720 million, the companies said late yesterday. (Full article: 656 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass